


CLAIMS

1. A compound of the following formula or a pharmaceutically acceptable salt thereof:



wherein:


A represents O, NH, or CH₂;

R₁ represents a single bond, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or a formula of Y₁-W, wherein Y₁ represents a lower alkyl group, a lower alkenyl group or dioxanyl; W represents a single bond or an oxygen atom; said lower alkyl group, lower alkenyl group, or lower alkynyl group may be substituted with one or more substituent(s), which is/are the same or different, selected from the group consisting of <substituent group β>;

R₂ represents a phenyl group, a naphthyl group, or a five- or six-membered aromatic or aliphatic heterocyclic ring having at least one atom selected from N, S, or O, selected from the group consisting of <substituent group α>, wherein said phenyl group, naphthyl group, aromatic or aliphatic heterocyclic ring may be substituted with one or more substituent(s), which is/are the same or different, selected from the group consisting of <substituent group β> and/or a lower alkyl group substituted with one or more substituent(s), which is/are the same or different, selected from the group of <substituent group β>; when A represents an oxygen atom, R₂ may represent hydrogen atom; with a proviso that A is NH and R₁ is CH₂, R₂ is not any of a substituted phenyl group, a hydroxymethyl-substituted naphthyl group, an unsubstituted pyridyl group, a hydroxymethyl-substituted pyridyl group, an unsubstituted thienyl group, a hydroxymethyl-substituted 2-thienyl group, a mono(hydroxymethyl)-substituted 3-thienyl group, an unsubstituted furyl group and a hydroxymethyl-substituted furyl group;

G represents a hexose group or a pentose group;

<substituent group α> represents the following:




and; <substituent group β > represents the following:

- 5 a hydroxyl group, a cyano group, a halogen atom, a nitro group, a carboxyl group, a carbamoyl group, a formyl group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxy group, a hydroxyl lower alkoxy group, a lower alkoxy carbonyl group, a lower alkyl carbamoyl group, a di-lower alkyl carbamoyl group, a carbamoyloxy group, a lower alkyl carbamoyloxy group, a di-lower alkyl carbamoyloxy group, an amino group, a lower alkyl amino group, a di-lower alkyl amino group, a tri-lower alkyl ammonio group, a lower alkanoyl

amino group, an aroyl amino group, a lower alkanoyl amidino group, a hydroxyl imino group, a lower alkoxy imino group, a lower alkyl thio group, a lower alkyl sulfinyl group, a lower alkyl sulfonyl group, a lower alkyl sulfonylamino group and a sulfamoyl group.


- 5 2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein G represents β -glucopyranosyl group; the positions of substitution of the hydroxyl groups on the indolopyrrolocarbazole ring are the 2- and 10-positions; R_1 represents a lower alkyl group; and R_2 represents a five- or six-membered aromatic or aliphatic heterocyclic ring having at least one atom selected from N, S, or O, selected from the group
- 10 consisting of the <substituent group α >.

3. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein the <substituent group α > represents the following:




- 15 and the <substituent group β > represents the following:
a hydroxyl group, a nitro group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxy group, and a lower alkoxy carbonyl group.

- 20 4. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein A represents O; the <substituent group α > represents the following:



the <substituent group β > represents the following:
a hydroxyl group, a lower alkanoyl group, a lower alkanoyloxy group, and a lower alkoxy carbonyl group.

5. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein A represents NH or CH₂; the <substituent group α> represents the following:



; and the <substituent group β> represents the following:

5 a hydroxyl group, a lower alkanoyl group, and a lower alkyl carbonyloxy group.

6. A compound according to claim 1 which is:

- 6-N-(2,5-dihydroxymethyl-3-thienylmethyl)amino-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 10 6-N-pyrazinylmethylamino-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 6-N-(4-quinolinylmethylamino)-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 15 6-N-(4-nitro-2-1H-pyrrolylmethyl)amino-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 6-N-(2-1H-pyrrolylmethyl)amino-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 20 6-N-(3-1H-pyrazolylmethyl)amino-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 6-N-(4-1H-imidazolylmethyl)amino-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 6-N-(2-methoxycarbonyl-6-pyridylmethyl)amino-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 25 6-N-(4-pyridylmethoxy)-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 6-N-(6-hydroxymethyl-2-pyridylmethoxy)-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione;
- 6-N-(3-hydroxymethyl-4-pyridylmethoxy)-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione; or
- 30 6-N-(2-(4-pyridyl)ethyl)-12,13-dihydro-2,10-dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione,
- or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6 as an active ingredient, together with a pharmaceutically acceptable

35

carrier or diluent.

8. An antitumor agent comprising the compound according to any one of claims 1 to 6 as an active ingredient, together with a pharmaceutically acceptable carrier or
5 diluent.